Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromatin accessibility profiling of terminal B cell differentiation [ATAC-Seq]

ABSTRACT: The terminal differentiation of B cells into antibody-secreting cells (ASCs) is a critical component of adaptive immune responses. Using our in vitro differentiation system, we combined RNA sequencing with ATAC-seq to characterize genomic events driving the ASC differentiation of human primary naive B cells. After an initial response to IL-4, cells that committed to an ASC fate downregulated the CD23 marker and IL-4 signaling, whereas cells that maintained IL-4 signaling did not differentiate. As demonstrated in the mouse, downregulation of the human ubiquitin ligase CBLB was required to free IRF4 from proteasomal degradation and produce levels needed for ASC differentiation. Our results evidenced two previously undocumented mechanisms driving human terminal B cell differentiation. Lastly, we showed that CD23-negative cells (i) carried the imprint of their previous activated B-cell status, (ii) were precursors of plasmablasts, and (iii) had a similar phenotype to in vivo pre-plasmablasts.

ORGANISM(S): Homo sapiens

PROVIDER: GSE136989 | GEO | 2020/11/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression profiling of terminal B cell differentiation [RNA-Seq]

Project description:The terminal differentiation of B cells into antibody-secreting cells (ASCs) is a critical component of adaptive immune responses. Using our in vitro differentiation system, we combined RNA sequencing with ATAC-seq to characterize genomic events driving the ASC differentiation of human primary naive B cells. After an initial response to IL-4, cells that committed to an ASC fate downregulated the CD23 marker and IL-4 signaling, whereas cells that maintained IL-4 signaling did not differentiate. As demonstrated in the mouse, downregulation of the human ubiquitin ligase CBLB was required to free IRF4 from proteasomal degradation and produce levels needed for ASC differentiation. Our results evidenced two previously undocumented mechanisms driving human terminal B cell differentiation. Lastly, we showed that CD23-negative cells (i) carried the imprint of their previous activated B-cell status, (ii) were precursors of plasmablasts, and (iii) had a similar phenotype to in vivo pre-plasmablasts.

2020-11-08 | GSE136988 | GEO

A dichotomy of gene regulatory associations during the activated B-cell to plasmablast transition [ChIP-seq]

Project description:The activated B-cell (ABC) to plasmablast transition is the cusp of antibody secreting cell (ASC) differentiation but is incompletely defined. We apply expression time-courses, parsimonious gene correlation network analysis, and ChIP-seq to explore this in human cells. The transition initiates with input signal loss leading within hours from cell growth dominant programs to enhanced proliferation, accompanied from 24h by ER-stress response, secretory optimization and upregulation of ASC features. Clustering of genomic occupancy for ASC transcription factors (TFs) IRF4, BLIMP1 and XBP1 with CTCF and histone marks defines distinct patterns for each factor in plasmablasts. Integrating TF-associated clusters and modular gene expression identifies a dichotomy: XBP1 and IRF4 significantly link to gene modules induced in plasmablasts, but not to modules of repressed genes, while BLIMP1 links to modules of ABC genes repressed in plasmablasts but is not significantly associated with modules induced in plasmablasts. Pharmacological inhibition of the G9A (EHMT2) histone-methytransferase, a BLIMP1 co-factor that catalyzes repressive H3K9me2 marks, leaves functional ASC differentiation intact but de-represses ABC-state genes. Thus, in human plasmablasts IRF4 and XBP1 emerge as the dominant association with ASC gene expression, while BLIMP1 links to repressed modules with particular focus in repression of the B-cell activation state.

2020-08-24 | GSE142493 | GEO

A dichotomy of gene regulatory associations during the activated B-cell to plasmablast transition [Microarray]

2020-08-24 | GSE142492 | GEO

Chromatin accessibility profiling of B cell subsets

Project description:Terminal B cell differentiation into antibody-secreting cells (ASC) is a critical process for adaptive immune responses. Although many efforts have been made in the recent years to decipher the cellular and molecular events sustaining this differentiation, both in mouse and human models, several key steps still need further elucidation. We used a combined RNA-seq and ATAC-seq approach to decipher the chromatin and gene expression events driving ASC differentiation from naive or memory B cells. Out goal with the dataset was to explore the divergent molecular properties of naive and memory B cells that sustain their differential abilities to differentiate into ASC.

2022-12-31 | GSE190457 | GEO

Expression profiling of B cells subsets

2022-12-31 | GSE190456 | GEO

Tumor rejection in Cblb-/- mice depends on IL-9 and Th9 cells

Project description:Casitas B lymphoma-b (Cbl-b) is a central negative regulator of cytotoxic T and NK cells, explaining its intracellular checkpoint function in cancer. Increasing evidence highlights the importance of CD4+ T helper cell populations (e.g., IL-9 producing T cells: Th9 cells) for anti-cancer immunity. We here provide experimental evidence that Cbl-b acts as rheostat favoring regulatory T cells (Treg) at the expense of Th9 cell differentiation. Adoptively transferred tumor-model antigen specific Cblb-/- Th9 cells exert superior anti-tumor activity leading to improved melanoma control in vivo. Accordingly, blocking IL-9 in melanoma cell-exposed Cblb-/- mice reverses their tumor rejection phenotype. Single cell RNA sequencing of in vitro differentiated Th9 cells from naïve T cells isolated from WT and Cblb-/- animals revealed the transcriptomic basis for increased Th9 cells differentiation. In summary, we here first establish IL-9 and Th9 cells as key anti-tumor executers in Cblb-/- animals. This knowledge may be helpful for future improvement of adoptive T cell therapies in cancer.

2022-04-30 | GSE173395 | GEO

Synergistic hepatoprotective effect of the TLR5 agonist CBLB502 and its downstream effector IL-22

Project description:We have shown that CBLB502 (CBLB) display hepatoprotective activities, and triggers a strong IL-22 release. To understand the hepatoprotection, we describe the response of isolated adult mouse hepatocyte to IL-22, CBLB, or IL-22 + CBLB exposure.

2021-10-28 | GSE160465 | GEO

ASC controls T-bet-dependent CTL differentiation and defines transplant outcome independent of the inflammasome

Project description:The adaptor protein ASC is known to facilitate caspase-1 activation essential for innate host immunity via the formation of the inflammasome complex - a multi-protein structure responsible for processing IL-1beta and IL-18 to their active moieties. Here we demonstrate that ASC-deficient CD8+ T cells fail to induce graft-versus-host disease (GVHD) and have impaired capacity for graft rejection and graft-versus-leukemia (GVL) activity. These effects are the result of an inability to differentiate into fully cytolytic, granzyme B-expressing effector cells, with a developmental bias instead towards CD127+KLRG1- memory CD8+ T cells. These alterations in differentiation are inflammasome-independent, since GVHD lethality and CTL differentiation are not altered in recipients of caspase-1-deficient T cells. We demonstrate that ASC binds to T-bet in CD8+ T and in the absence of ASC, the binding of T-bet to the granzyme B promoter is impaired. Thus, the inhibition of ASC represents an attractive therapeutic target to manipulate transplant outcomes. Single colour, Illumina MouseRef-8 v2.0 Beadarrays.

2016-04-01 | E-GEOD-78755 | biostudies-arrayexpress

Dissecting the role of CBLB in human T cell activation and suppression

Project description:Cbl-b is a negative regulator of T cell activation and in murine models a lack of CBLB results in resistance of T effectors to Tregs, a feature of T cells in many autoimmune diseases. Here, we used trackable gene-editing approaches to knock out CBLB in primary human CD4+ T cells. We found that CBLB-KO CD4+ T cells were hyper-proliferative and produced excess amounts of IL-2 at baseline and upon TCR stimulation. CBLB-KO CD4+ T cells were resistant to Treg suppression in vitro, which was partially reversed by blockade of IL-2. RNAseq and puromycin incorporation assays demonstrate that CBLB-KO CD4+ T cells can overcome Treg suppression on the transcriptional and translational level resulting in the overproduction of cytokines to drive the proliferation and activation of Teffs. These findings also highlight a potential mechanism of Teff resistance in human autoimmune disease and the power of gene editing of primary T cells to explore disease mechanisms.

2022-07-19 | GSE198810 | GEO

ASC controls T-bet-dependent CTL differentiation and defines transplant outcome independent of the inflammasome

2016-04-01 | GSE78755 | GEO